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Abstract
Background: There have been dramatic increases over the past 20 years in the number of nonacademic, private-sector
physicians who serve as principal investigators on US clinical trials sponsored by the pharmaceutical industry. However,
there has been little research on the implications of these investigators’ role in clinical investigation. Our objective was to
study private-sector clinics involved in US pharmaceutical clinical trials to understand the contract research arrangements
supporting drug development, and specifically how private-sector physicians engaged in contract research describe their
professional identities.
Methods and Findings: We conducted a qualitative study in 2003–2004 combining observation at 25 private-sector
research organizations in the southwestern United States and 63 semi-structured interviews with physicians, research staff,
and research participants at those clinics. We used grounded theory to analyze and interpret our data. The 11 private-sector
physicians who participated in our study reported becoming principal investigators on industry clinical trials primarily
because contract research provides an additional revenue stream. The physicians reported that they saw themselves as trial
practitioners and as businesspeople rather than as scientists or researchers.
Conclusions: Our findings suggest that in addition to having financial motivation to participate in contract research, these
US private-sector physicians have a professional identity aligned with an industry-based approach to research ethics. The
generalizability of these findings and whether they have changed in the intervening years should be addressed in future
studies.
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Introduction
Pharmaceutical clinical trials are increasingly being conducted
in the private sector as part of a growing global contract research
system [1–3]. In the United States, a major shift in the locus of
pharmaceutical research has taken place in the last two decades.
Whereas the majority of clinical trials were completed in academic
medical centers in the 1980s, estimates reported in 2005 showed
that more than 70% of US trials were conducted by nonacademic
physicians [4]. Community physicians have largely replaced their
academic counterparts as principal investigators (PIs) on pharma-
ceutical trials [1,5].
US medicine has changed significantly in the past 30 years. As a
direct response to the perception that US health care expenditures
had reached a point of ‘‘crisis,’’ health care reforms in the 1970s
and 1980s aimed to limit excesses in health care spending [17–19].
While the reality of this crisis is open to debate, it is a common
perception that physicians’ payments have decreased significantly
due to managed care [20–22], whereas practice operational costs
have increased [23]. Pham et al. report that US physicians feel
‘‘beleaguered’’ and forced into becoming more ‘‘business-orient-
ed’’ [22]. Physicians have joined larger, multispecialty practices in
order to defray costs and liability [24]. Additionally, many have
referred patients to their privately owned ancillary service centers
[25]. This focus on the business of medicine has raised concerns
that medical professionalism in the US, particularly in terms of
physicians’ values and ethics, has been affected [26].
The pharmaceutical industry has provided an opportunity for
US physicians in private practice to serve as PIs on clinical trials
[11,22,27,28]. The number of US private-sector physicians
conducting pharmaceutical trials increased from 4,000 in 1990
to 20,250 in 2010 [29], with research contracts now worth more
than US$11 billion annually [30]. This enormous growth in the
number of private-sector physicians involved in contract research
is due in part to their replacing academic physicians on
pharmaceutical clinical trials, but it is also due to simultaneous
exponential growth in the number of clinical trials initiated by
industry during this same time period [31].
Pharmaceutical contract research is profitable to US physicians
because of the fee-for-service payment system that structures
companies’ remuneration of PIs [32]. Specifically, beginning with
informed consent, PIs get paid for each step in the screening
process, and for each study procedure, history and physical, and
blood draw. Reimbursement rates are significantly higher than
what Medicare pays for the same services [1]. An American
College of Physicians’ report found that contract research provides
individual physicians income of up to US$300,000 annually [33].
Although the potential revenue from contract research is
substantial, this income is not without ethical risks. Nonetheless,
there is little oversight of financial conflicts of interest in the private
sector compared to academic settings, raising concern that if per
capita payments are inappropriately high, private-practice physi-
cians might make recruitment decisions that are not in their
patients’ best interest [34].
Bodenheimer has argued that certain conditions enabled the
development of a private-sector clinical trials industry [5]. He
explains that, originally, academic medical centers provided (1)
trial design expertise, (2) a patient population from which to draw,
and (3) prestige and publishing experience. However, the
combination of private-sector companies, private-sector physi-
cians, and high-level scientists and physicians employed directly by
pharmaceutical companies and contract research organizations
has proved a more advantageous drug development model [5].
This model is based on the premise that speeding up clinical
development is an important way for companies to increase their
profits on patented products and that private companies are more
efficient than are academic medical centers [35]. Indeed, it has
been reported that private companies complete trials up to three
months faster than academic medical centers, resulting in about
US$90 million in additional earnings on each new drug [36].
In spite of the dramatic shift in who serves as PIs on industry
clinical trials in the US, there has been little research on the
implications of this trend [1,3,5]. The purpose of our study was to
explore the outsourcing of clinical trials to US private-sector
research clinics, paying particular attention to the different groups
involved in the research enterprise (e.g., pharmaceutical company
representatives, physicians, study coordinators, and research
participants) and to the everyday practices associated with
conducting clinical trials (e.g., recruitment of participants,
informed consent processes, and study compliance). The data
were collected as part of an institutional ethnography that was
conducted between October 2003 and September 2004 [1]. The
study was designed in an open-ended way because little empirical
research had been conducted on the clinical trials industry and
there were few guides indicating specific areas in need of
investigation. In June 2011, the authors completed a second-order
analysis of the data to use the findings of the empirical project to
generate insights about the growing scholarly literature that has
cited evidence of an increasing array of unscientific research
practices perpetrated by the pharmaceutical industry [3,4,6–16].
This paper reports on our findings that private-sector PIs view
monetary incentives, clinical research, and ethics in unexpected
ways.
Methods
Our study of the clinical trials industry used a qualitative
research design, consisting of semi-structured interviews and
observation that took place between October 2003 and September
2004 at 25 US private-sector research organizations, such as
private practices, dedicated research sites, and large (nonacadem-
ic) hospitals. Two cities in the southwest US were selected for the
study because of the preponderance of private-sector clinics in this
region, according to information in an industry clinical trial
clearinghouse database (CenterWatch; http://www.centerwatch.
com). The database was also used to identify and contact
individual sites. All sites in the two cities were contacted and
invited to participate in the project. Although no incentives were
offered to promote participation, 75% of sites in one city and 50%
of sites in the other city agreed to take part in observation and
interviews. According to information listed in the database, there
was no discernable difference between sites that agreed or refused
to participate, in terms of the types of studies conducted, size of the
clinical trials operation, or experience of the site. Clinic specialties
included family and internal medicine, gastroenterology, neurol-
ogy, pediatrics, rheumatology, and urology. As we discuss in more
detail below, all sites conducted clinical trials outside of their
specialty area. The majority of sites conducted trials to test the
efficacy of new products for conditions that already had safe and
effective treatments on the market (e.g., allergies, asthma,
hypercholesterolemia, and insomnia), as has been identified
elsewhere [6]. Only one site consistently tested products for life-
threatening conditions (e.g., AIDS or cancer). One site specialized
in early phase studies with healthy volunteers.
Semi-structured interviews (Text S1) with 63 informants were
clustered to get the perspective of multiple employees at each site,
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including 12 PIs, 18 coordinators, three recruiters, and seven non-
physician site administrators, as well as 14 research participants
and nine representatives of pharmaceutical companies. Interview-
ees were selected based on their availability during observational
visits. For instance, during some research visits, the only person
present in the clinic was a research coordinator; at other clinics,
research visits generated interviews with multiple informants. The
size of a clinic and its level of activity limited the number of
interviews—and the variety of people available for interviews—at
each site. No one who was asked to participate in an interview
refused. Interviews were conducted until saturation was reached
[37], meaning that additional interviews ceased to provide data
that generated new insights or information about contract
research. Interviews lasted an average of 40 min. This paper
draws on our entire dataset, including themes and findings from
observations at all 25 research clinics and all 63 interviews.
Because of our focus on physicians in this paper, we quote most
extensively from the interviews with 11 physician-investigators
who served as PIs in contract research. Physicians in our sample
were representative of the national demographics of industry-
funded investigators [38]: ten men and one woman; ten white and
one Hispanic. Most physicians were in their 40 s, with an age
range from mid-30s to late-70s, with a broad range of experience
conducting trials (1–20 y).
Observation in clinics was focused primarily on interactions
between PIs and participants, as well as between coordinators and
participants. Observation ranged from a single visit on one day to
multiple visits spanning several months. Field notes were used to
capture observational data [39]. In interviews, informants were
asked questions about their job responsibilities as well as about
their experiences working in clinical research, how research had
changed over time, and what types of changes they would like to
see in the future. Specific interview questions for PIs also solicited
their perceptions of research ethics and of their responsibilities to
participants, pharmaceutical companies, and science. All data
were collected by one of the authors (J. A. F.), who is trained in
qualitative sociological methods. This author also transcribed all
the interviews in full and contacted interviewees to give them the
opportunity to edit their transcripts. The study was reviewed and
approved by the Institutional Review Board of Rensselaer
Polytechnic Institute. Written informed consent was obtained
from all participants. All research clinics and informants were
given confidentiality as part of their participation in the study.
In keeping with a methodology of grounded theory [40], there
were no predefined theoretical or conceptual frameworks or
specific hypotheses identified for analysis prior to data collection.
In addition, multiple conceptual frameworks were developed
through the process of interpreting the findings from the project.
As with most grounded theory projects, the data analysis relied on
a multi-staged process of coding field notes and interviews in their
entirety for core and emerging categories. All the coding was done
by one of the authors (J. A. F.). Coding was multi-staged in order
to revisit the data multiple times for depth of analysis and for the
creation of cross-references among the data and the categories
coded. Coding during the data collection period was done by
creating detailed memos at the conclusion of site visits and by
repeated, fine-grained reading of transcripts and field notes for
additional themes that emerged as important. This process helped
to guide subsequent observation and interview techniques by
highlighting areas of inquiry that needed further exploration. In
the final stage of coding after the data collection period, more
subtle codes were added that aimed to create subcategories within
emergent themes. The current analysis was validated in a 2-fold
way by both authors: first, by reflecting on themes in light of the
published literature on the topic and, second, by attending
industry conferences and reading industry publications designed to
provide advice and commentary on the clinical trials industry.
Results
Our research revealed trends in why US physicians become PIs
on industry clinical trials and how they develop their professional
identities as contract researchers. By ‘‘professional identities’’ we
are referring to how physicians incorporate into their existing
clinical roles their experience of the rights and responsibilities that
accompany contract research. We discuss three aspects of their
identities shaped by (1) their motivations to conduct clinical trials,
(2) an orientation that privileges business over science, and (3) an
industry-based sense of research ethics.
Motivations
All private-sector physicians we interviewed reported the
financial incentives of participating in pharmaceutical trials as
the most salient for becoming contract researchers. The dominant
view among all our informants—physicians, research staff, and
pharmaceutical company representatives alike—is that contract
research is a lucrative activity to integrate into a clinical practice.
One physician said:
We’re paid less and less for the work that we do. In fact,
we’re paid about 50% of what we made 20 years ago…. So
one of the ways that we have to try to offset that [trend] is to
find an alternative source of revenue; getting into research
was a way to do that.
Not only is contract research viewed as more profitable than
standard care, but the physicians also viewed it as a way to shorten
their hours in the clinic because many study activities can be
delegated to nurse coordinators. An administrator in charge of
recruiting additional private-practice physicians as PIs for a large
national company explained:
It’s a profitable industry. Doctors want to do the research
because it’s profitable. They don’t want to spend the time to
do it, and right now, the way the industry’s set up, they can
do that. They can hire a nurse and a couple coordinators to
essentially run 98% of the study for them, make them a lot of
money, and they do minimal work.
Indeed, several study coordinators in our sample joked about how
clinical research helped physicians improve their golf games (n = 8,
44%). Our observations confirm that at the majority of the 25 sites
at which we conducted our research (n = 18, 72%), the PIs were
frequently absent from the clinic.
Financial incentive was not the only reason physicians in our
sample gave for becoming contract researchers. The physicians
also noted that clinical research is intellectually rewarding and
elevates their professional status. In addition, almost half of the
physicians (n = 5, 45%) found clinical trials to be a benefit to their
patients or the broader community. One physician said:
What we do here is I can give out free blood pressure,
diabetes, and lipid medication as well as free blood pressure,
diabetes, and lipid care to the community…. A lot of my
patients come from a lower socioeconomic background, and
so it’s very nice because I sort of had the ideal when I went
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into medicine that I wanted to do that, but somehow you get
taken away from that as years go by.
In spite of these other perceived benefits of becoming an
investigator, our data show that financial gain tends to be the
initial motivation for physicians to seek a study contract.
Business versus Science
Our research revealed that PIs perceive their roles in terms of
business rather than science. In fact, because of the rapid growth
of this industry, many physicians in our sample (n = 9, 82%)
asserted that PIs must be competent businesspeople in order to
succeed economically in contract research. As one physician
explained:
There’s a lot of business in the industry. And medical
training is certainly important because there’s, of course, a
lot of medicine in there; but that’s not enough, it’s not
sufficient. Clinical trials is a specialty unto itself, both the
business of clinical trials as well as the ethics of clinical trials,
dealing with IRBs [institutional review boards], dealing with
pharmaceutical companies, dealing with a whole bunch of
things, as well as how to manage a large [research] center.
As evidence of this professional identity, our interviewees differen-
tiated themselves from their academic counterparts by their participa-
tion in different conferences and sessions to fulfill their continuing
medical education requirements: private-sector PIs often attend
business-related panels whereas academic PIs tend to participate in
panels devoted to science and clinical advances. One physician said:
I go religiously to the [annual specialty meeting] strictly for
business development purposes…. That doesn’t mean that I
don’t like and appreciate the science…. I try to understand
the direction each pharmaceutical company goes when
they’re using this compound in this indication, which is
targeting blah blah blah, whatever it is.
While conference session attendance is only one small part of
physicians’ professional identities, our interviewees also claimed
that investigator competency is not based on clinical expertise but
on savvy in managing trials. Private-sector PIs believe that they
offer something to the pharmaceutical industry that academics do
not—the ability to carry out a diverse range of trials more quickly
and effectively—regardless of their medical specialty. One
physician explicitly compared the expertise of private-sector
trialists and academic physicians:
What do we bring that the academic medical centers don’t?
We bring a techné—it’s an old Greek word—as opposed to a
science. Pharmaceutical companies can hire the scientists,
but at some point the end has to be executed, so that’s what
we bring to the table: our capability, interest and motivation,
drive. Because that’s it for most of us—not all, but most of
us—in the private sector, it is a priority for us to succeed….
What [we] offer is an execution.
Moreover, none of the PIs in our sample ever participated in
analyzing trial data or authoring publications.
In our sample of research organizations, we also found that
private-sector PIs are involved in a broad range of therapeutic
areas. Because the focus is on ‘‘execution’’ rather than clinical
expertise per se, private-sector physicians routinely served as PIs
on clinical trials for diseases outside of their specialty training
(n = 9, 82%). One physician—who was trained as a neurologist but
had ongoing studies for depression, weight loss, and gastroesoph-
ageal reflux disease, among others—explained his approach:
I do not do original research; I do contract research. I read
the neurology literature; I do not read the psychiatry
literature; I don’t read the obesity literature. You know, for
certain things, I’m pretty smart. And in other things, I don’t
even pretend that I’m smart about those. But I’m very good
at running clinical trials, so in a sense…I’m a highly skilled
practitioner of clinical trials who has an appreciation for the
science, plus the scientific need, plus the fact that they rely
on the data that we give them to be scientifically valid
because there are lives at stake in that data. But I’m not a
scientist.
The predominant perception we found among our informants—
including representatives from pharmaceutical companies—is that
skilled contract researchers can conduct any clinical trial provided
that they can recruit the relevant patient populations into those
studies.
Ethics
We found that reframing clinical trials as a business endeavor is
also associated with physicians’ perceptions of research ethics.
When asked about ‘‘ethical’’ issues that come up in clinical trials,
physicians in our sample focused instead on responsible conduct of
research. For example, one physician explained that the PI’s
responsibility is to be ‘‘very conscientious, and they also do
everything ethically based on the protocol, regulations, FDA [US
Food and Drug Administration], etc.’’ In other words, PIs in our
sample answered by talking about the importance of following the
protocols and avoiding misconduct or fraud. Surprisingly,
physicians had a lot to say about the temptations of ‘‘massaging
the data,’’ as this statement by an experienced PI illustrates:
There’s all sorts of ways people will justify blurring lines of
distinction, which may or may not be clear actually.
Throwing away a lab value is way over the line, right?
Does it have to be fudged when you’re doing a blood
pressure study and this person is two points out of range on
their fifth visit, and you’ve already put in a month of time on
that person? I don’t know. Does that betray the spirit of
what you’re trying to do? As opposed to ten points out of
line, then they’re out. So I can see how individual people will
sort of figure out where they’re comfortable on that.
According to another physician:
Obviously, there’s an ethical standard that the physicians
will be following, but, of course, everyone knows there’s
shades of pressure around your proper ethical behavior
which may be trying to push or negotiate certain decisions
that the physician is making or certain opinions that they’re
forming, to comply or go along better with others [at
sponsoring companies] who are pressuring him or her [to
enroll/retain participants].
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What was striking in our research was that more traditional
views of ethics, especially the investigator’s responsibility to trial
participants, were not explicitly evident. In part, this might be due
to the prepackaged nature of the contract research enterprise, but
it might also be due to private-sector physicians’ lack of scientific
training and their trust in pharmaceutical companies. For
example, one physician explained:
You know, we really don’t have a lot of leeway in the
scientific department. I mean, if somebody says we have this
really great drug that works for blood pressure, I have no
idea how this damn thing works! But I’m still going to go
down the hall and do physicals and check blood pressures
and sign off adverse events…. I have no idea about science!
Whether that’s good or bad or indifferent. That’s why we’re
doing the research, and I figure someone’s putting several
million dollars, or $20 million into doing this study, so they
must believe in what they’re doing.
In other words, for this physician, the amount of money that
pharmaceutical companies invest in the development of their
products becomes the basis of trust that these companies are
making scientifically sound and ethical decisions in the design of
clinical trials.
Discussion
The results from our study corroborate earlier research
indicating that US private-sector physicians are motivated to
participate as PIs in pharmaceutical clinical trials for financial
reasons [5,11,22,32]. We also discovered that while financial
incentives might be the most salient, at least initially, physicians
also report other advantages associated with contract research:
intellectual reward, increased professional status, and benefit to
their patients and communities.
Beyond private-sector physicians’ motivations to participate in
pharmaceutical trials, our findings reveal that the financial aspects
of contract research are aligned with their professional identities.
Instead of seeing themselves as scientists or researchers, they see
themselves as trial practitioners and as businesspeople. At
conferences the physicians in our sample attend sessions geared
toward the business aspect of trials, suggesting that they might not
consider additional knowledge about pharmaceutical science or
medical practice to be of foremost importance for their
professional development. This may help to explain the rise of
industry conferences that are entirely dedicated to specific business
aspects of trials, including patient recruitment [41]. Additionally, it
was an unexpected finding that the financial incentive to
participate in contract research propelled the private-sector
physicians in our sample to serve as investigators on trials for
investigational drugs in a broad range of therapeutic areas. That
they often work on the margins of their specialized training
provides one potential explanation for why the private-sector
physicians did not see themselves as scientists and claimed little
insight into the mechanisms by which particular drugs work.
Unlike traditional investigator-initiated research, such as studies
funded by US National Institutes of Health, the prepackaged
nature of contract research means that physicians do not need to
have expertise in research design and methods because they have
limited input into trial protocols [1]. As a result, private-sector
investigators, who by self-report in our study are not interested in
or trained to understand the science, potentially facilitate the
pharmaceutical industry’s ability to exert more control over
information about their products, including any negative data
generated from clinical trials [9,12,13,42–47]. The literature has
suggested that pharmaceutical companies are interested in
controlling their trial datasets so that individual PIs do not have
access to data collected at all participating investigative sites and
any resulting publications can be prepared by ghostwriters
[6,10,16]. Our findings indicate that this arrangement tends to
be acceptable to private-sector physicians who rarely—if ever—
participate in analyzing trial data or authoring publications.
Private-sector physicians incorporate ethics into their identities
in unique ways as well. It was revealing that when asked about
ethics, the physicians in our sample always answered the question
in terms of responsible conduct of research. Instead of being
concerned with the dominant domain of research ethics—the PI’s
responsibilities to research participants—they understood their
primary ‘‘ethical’’ responsibility as providing accurate data to the
companies that hired them. Within the context of their work, this
makes sense. Contract researchers do not design the studies, nor
are they given much opportunity to provide input on the
protocols. Additionally, private-sector physicians often do not
have institutional review boards associated with their clinics, and
the review of clinical trial protocols is handled by centralized
commercial companies [8]. These two factors imply that to a large
extent PIs must trust that the sponsoring company has designed a
scientifically valid and ethical trial and that the centralized
institutional review board has established appropriate guidelines
for the protection of enrolled research participants [27]. What this
suggests, however, is that physicians do not perceive the potential
ethical conflicts that emerge as a result of their dual roles as health
care provider and clinical researcher when they are conducting
clinical trials that enroll their own patients.
There are, of course, limitations to our study. Although we
included a diverse sample of research organizations in our study
and reached thematic saturation with our interviews, the number
of physicians we interviewed was small. We limited our study to
private-sector research in one geographical region of the US.
While the published literature indicates that the trends we found in
our research are likely generalizable to other regions of the US, the
context differs dramatically in countries with national health care
systems, so it is likely that private-sector PIs characterize their roles
differently in other settings. We must also note that our data were
collected eight years ago, so it is unclear how physicians’ identities
might have changed in response to subsequent changes in the
funding of contract research, such as the rise in seeding trials, or
the broader health care environment. In addition, our study was
not designed to investigate physicians’ professional identities as
contract researchers. Instead, what we report here are unprompt-
ed themes identified during data analysis. To better understand
private-sector PIs, future studies are needed to compare their
identities with those of academic physicians and to investigate how
differences in identity might influence the execution and results of
contract research. Future studies could also compare cross-
national differences in the perceptions and practices of pharma-
ceutical investigators. Indeed, contract research is a global
enterprise [2], and our study highlights the need to understand
better the changes that have occurred in the conduct of
pharmaceutical clinical trials worldwide.
Conclusions
The focus of this paper has been on the participation and
professional identities of US private-sector physicians who conduct
pharmaceutical clinical trials. While a greater number of
physicians in more diverse settings are now engaged in pharma-
ceutical research than were 20 years ago, our data have potentially
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troubling implications for drug development. We found that the
private-sector physicians interviewed identify primarily with the
business rather than the science of contract research. In addition,
our findings indicate that the private-sector PIs aligned their sense
of research ethics with industry—ensuring the responsible conduct
of research—rather than foregrounding the interests of research
participants. Because these private-sector PIs are largely motivated
by financial gain as opposed to making a contribution to science,
we suggest that the professional identity of private-sector PIs may
inadvertently offer pharmaceutical companies the ability to exert
more control over their proprietary information and clinical trial
data. This provides one explanation as to why, despite the
participation of physicians as PIs, pharmaceutical companies have
been able to suppress negative trial data and selectively publish
study results [9,12,13,42–45].
We do not question that contract researchers are able to execute
studies professionally and effectively, even when they are business-
oriented. That said, private-sector physicians are an important
part of a different type of contract research system, one that has
become the dominant model of conducting pharmaceutical
clinical trials in the US and around the world [1–3,48]. This
change can be thought of as facilitating a shift in drug
development in which protocols are developed and study results
are analyzed in-house by pharmaceutical companies—sometimes
in conjunction with their marketing departments [6,7]. We suggest
that the lack of interest or expertise in the science of clinical
research reported by private-sector PIs in our study would
facilitate a research enterprise that is characterized by high levels
of industry control over research protocols, data analysis, and
dissemination of information about new pharmaceuticals.
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Editors’ Summary
Background. Before a new drug can be used routinely by
physicians, it must be investigated in clinical trials—studies
that test the drug’s safety and effectiveness in people. In the
past, clinical trials were usually undertaken in academic
medical centers (institutes where physicians provide clinical
care, do research, and teach), but increasingly, clinical trials
are being conducted in the private sector as part of a
growing contract research system. In the US, for example,
most clinical trials completed in the 1980s took place in
academic medical centers, but nowadays, more than 70% of
trials are conducted by nonacademic (community) physi-
cians working under contract to pharmaceutical companies.
The number of private-sector nonacademic physicians
serving as principal investigators (PIs) for US clinical trials
(the PI takes direct responsibility for completion of the trial)
increased from 4,000 in 1990 to 20,250 in 2010, and research
contracts for clinical trials are now worth more than US$11
billion annually.
Why Was This Study Done? To date, there has been little
research on the implications of this change in the conduct of
clinical trials. Academic PIs are often involved in both
laboratory and clinical research and are therefore likely to
identify closely with the science of trials. By contrast,
nonacademic PIs may see clinical trials more as a business
opportunity—pharmaceutical contract research is profitable
to US physicians because they get paid for every step of the
trial process. As a result, pharmaceutical companies may now
have more control over clinical trial data and more
opportunities to suppress negative data through selective
publication of study results than previously. In this qualita-
tive study, the researchers explore the outsourcing of clinical
trials to private-sector research clinics through observations
of, and in-depth interviews with, physicians and other
research staff involved in the US clinical trials industry. A
qualitative study collects non-quantitative data such as how
physicians feel about doing contract research and about
their responsibilities to their patients.
What Did the Researchers Do and Find? Between
October 2003 and September 2004, the researchers ob-
served the interactions between PIs, trial coordinators
(individuals who undertake many of the trial activities such
as blood collection), and trial participants at 25 US research
organizations in the southwestern US and interviewed 63
informants (including 12 PIs) about the trials they were
involved in and their reasons for becoming involved. The
researchers found that private-sector physicians became PIs
on industry-sponsored clinical trials primarily because con-
tract research was financially lucrative. The physicians
perceived their roles in terms of business rather than science
and claimed that they offered something to the pharma-
ceutical industry that academics do not—the ability to carry
out a diverse range of trials quickly and effectively, regardless
of their medical specialty. Finally, the physicians saw their
primary ethical responsibility as providing accurate data to
the companies that hired them and did not explicitly refer to
their ethical responsibility to trial participants. One possible
reason for this shift in ethical concerns is the belief among
private-sector physicians that pharmaceutical companies
must be making scientifically and ethically sound decisions
when designing trials because of the amount of money they
invest in them.
What Do These Findings Mean? These findings suggest
that private-sector physicians participate as PIs in pharma-
ceutical clinical trials primarily for financial reasons and see
themselves as trial practitioners and businesspeople rather
than as scientists. The accuracy of these findings is likely to
be limited by the small number of PIs interviewed and by the
time that has elapsed since the researchers collected their
qualitative data. Moreover, these findings may not be
generalizable to other regions of the US or to other
countries. Nevertheless, they have potentially troubling
implications for drug development. By hiring private-sector
physicians who see themselves as involved more with the
business than the science of contract research, pharmaceu-
tical companies may be able to exert more control over the
conduct of clinical trials and the publication of trial results
than previously. Compared to the traditional investigator-
initiated system of clinical research, this new system of
contract research means that clinical trials now lack the
independence that is at the heart of best science practices, a
development that casts doubt on the robustness of the
knowledge being produced about the safety and effective-
ness of new drugs.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001271.
N The ClinicalTrials.gov website is a searchable register of
federally and privately supported clinical trials in the US; it
provides information about all aspects of clinical trials
N The US National Institutes of Health provides information
about clinical trials, including personal stories about
clinical trials from patients and researchers
N The UK National Health Service Choices website has
information for patients about clinical trials and medical
research, including personal stories about participating in
clinical trials
N The UK Medical Research Council Clinical Trials Unit also
provides information for patients about clinical trials and
links to information on clinical trials provided by other
organizations
N MedlinePlus has links to further resources on clinical trials
(in English and Spanish)
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